Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer

Area of Science:

• Gynecologic Oncology
• Medical Oncology
• Clinical Trials

Background:

• Previous reviews indicated neoadjuvant chemotherapy (NAC) before surgery improves survival compared to radiotherapy for cervical cancer.
• The comparative effectiveness of NAC followed by surgery versus surgery alone for cervical cancer remains unclear.
• This review focuses on early or locally-advanced cervical cancer patients who have not received prior interfering treatments.

Purpose of the Study:

• To systematically evaluate the role and impact of neoadjuvant chemotherapy in women diagnosed with early or locally-advanced cervical cancer.
• To compare outcomes of neoadjuvant chemotherapy followed by surgery against surgery alone in cervical cancer management.

Main Methods:

• Systematic search of multiple databases (CENTRAL, MEDLINE, LILACS, PDQ) for published and unpublished randomized trials up to August 2012.
• Inclusion criteria comprised randomized trials comparing neoadjuvant chemotherapy with surgery in untreated early or locally-advanced cervical cancer.
• Primary outcome was overall survival (OS); secondary outcomes included progression-free survival (PFS), recurrence rates, resection rates, and surgical morbidity.

Main Results:

• Six trials involving 1078 women were included. Neoadjuvant chemotherapy significantly improved both OS (HR 0.77, P=0.02) and PFS (HR 0.75, P=0.008).
• Local recurrence rates favored neoadjuvant chemotherapy (OR 0.67, P=0.04), though not significant in random-effects analysis. Distant recurrence and resection rates showed non-significant trends favoring NAC.
• Exploratory analyses revealed a significant decrease in adverse pathological findings, including lymph node status (OR 0.54, P<0.0001) and parametrial infiltration (OR 0.58, P=0.002), with NAC.

Conclusions:

• Neoadjuvant chemotherapy demonstrates significant improvements in overall survival and progression-free survival for cervical cancer patients.
• While trends favor neoadjuvant chemotherapy for other outcomes, the evidence base is limited, suggesting a need for further research.
• Neoadjuvant chemotherapy may offer a survival benefit over surgery alone in early-stage or locally-advanced cervical cancer, warranting careful consideration in treatment planning.